Conference Reports for NATAP

AASLD 61th Annual Meeting of the American Association for the Study of Liver Diseases Boston, MA, Hynes Convention Center October 30-November 3, 2010 Back

Pharmacokinetics, Safety, and Tolerability of PSI-352938, a Novel Nucleotide Polymerase Inhibitor for HCV, Following Single Ascending Oral Doses in Healthy Subjects       Reported by Jules Levin AASLD 2010 Nov 2 Boston   William T. Symonds1, Jill M. Denning1, Efsevia Albanis1, Melanie T. Cornpropst1, Robert Wright2, Alexander Lai2, M. Michelle Berrey1 1. Pharmasset, Inc., Princeton, NJ, 2. Covance Clinical Research Unit, Inc, Madison, WI